Vireo Growth Inc just refinanced its way out of cannabis debt purgatory. The company secured $60 million in real estate financing at 8.5% annual interest, maturing in April 2034, backed by cultivation and production facilities in New York and Florida. About $49 million replaces existing senior debt on the Johnstown, New York facility. The other $11 million funds a cultivation and production property acquisition in Palatka, Florida for its Green Dragon operations.
What changed between 15% and 8.5%?
The lenders. Back in May, Vireo bought its 389,000 square foot Johnstown facility from an Innovative Industrial Properties subsidiary for $88.5 million, a property it had previously leased. Part of that purchase was a $49 million seller note at 15% interest, maturing in May 2027, plus a $41 million loan from Chicago Atlantic. That is cannabis industry money: expensive, short dated, and priced for risk.
The new $60 million comes from a US commercial bank and an institutional lender, neither named in the announcement. That is traditional money, priced at 8.5% with a 2034 maturity. The rate cut roughly in half and the term stretched by seven years tell you everything about how the two sides of the market view the same collateral.
Why is property backed debt the lane traditional lenders are entering through?
Because real estate is the one part of a cannabis company a bank can underwrite without touching the plant. A commercial bank does not need a view on wholesale flower prices to lend against a 389,000 square foot industrial facility in New York. The collateral is the building. The cannabis license is the tenant’s problem.
That is why this deal matters beyond Vireo. It is a template: package the hard assets, borrow against the property, and let the cannabis operations sit behind a familiar commercial real estate structure. Expect every MSO with owned facilities to be running the same playbook, because the spread between 15% specialty debt and 8.5% bank debt is the difference between surviving and compounding. I covered the same scale versus survival tension in Tilray’s record revenue quarter, where the balance sheet decided the story.
Is this the institutional capital thesis happening in real time?
Yes, and it arrived through the side door. This week’s post argued that rescheduling is a starting gun, not a finish line, and that the interesting question is which companies get underwritable before the gates open. Vireo just demonstrated the answer: get your properties financeable, and the banks show up before the policy is finished.
The unnamed lenders are the tell. A US commercial bank and an institutional lender do not put $60 million into cannabis facilities because of vibes. They did the credit work, priced the risk at 8.5%, and took a nine year view. That is institutional behavior, and it is happening while federal policy is still mid transition. More on the capital side of this industry in the cannabis business collection.
Frequently Asked Questions
- What did Vireo secure? $60 million in real estate financing at 8.5% annual interest, maturing in April 2034, backed by cultivation and production facilities in New York and Florida.
- How is the money split? About $49 million refinances existing senior debt on the Johnstown, New York facility, and $11 million funds a cultivation and production property acquisition in Palatka, Florida supporting Green Dragon operations.
- What did the old debt cost? A $49 million seller note from Innovative Industrial Properties at 15% interest maturing in May 2027, plus a $41 million loan from Chicago Atlantic, from the May purchase of the Johnstown facility for $88.5 million.
- Who are the new lenders? A US commercial bank and an institutional lender, neither identified in the announcement, which itself signals how normalized this lending is becoming.
- Why does this deal matter to the industry? It proves traditional lenders will finance cannabis infrastructure through property backed structures at near conventional rates, and every operator with owned real estate should be studying the playbook.